We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mauna Kea Technologies SA | EU:ALMKT | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.1724 | 0.1722 | 0.1796 | 0.1724 | 0.1722 | 0.1722 | 924 | 08:22:19 |
From Oct 2024 to Dec 2024
Article L233-8-II of the Commercial Code Article 223-16 of the General Regulations of the AMF
Regulatory News:
Listing: Euronext Growth Paris ISIN code: FR0010609263, Ticker: ALMKT Website: www.maunakeatech.com
Date
Number of shares comprising
the capital in circulation
Total number of voting rights
Gross Total (1)
Net Total (2)
October 31, 2024
67,219,997
68,512,596
68,425,638
650,000 new shares were issued during the month under the PACEO financing facility, the characteristics of which are described in the press releases of May 31, 2023 and July 25, 2024.
(1) The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In accordance with Article 223-11 of the General Regulations of the AMF, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights.
(2) The net number of voting rights (or voting rights "exercisable in General Meeting") is calculated without considering the shares with suspended voting rights. It is published for proper public information in accordance with the AMF recommendation of July 17, 2007.
***
About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106893811/en/
Mauna Kea Technologies investors@maunakeatech.com
NewCap - Investor Relations Aurélie Manavarere / Thomas Grojean +33 (0)1 44 71 94 94 maunakea@newcap.eu
1 Year Mauna Kea Technologies Chart |
1 Month Mauna Kea Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
